Table 1.
Lung cancer patients - samples characteristics.
| Sample (response to chemotherapy) | Total Proteins [mg·mL−1] | Albumin[%] | Sex | Smoking | Lung Cancer Type |
|---|---|---|---|---|---|
| LC-a1 (smLC) | 75.0 | 58.7 | M | Yes | Adenocarcinoma |
| LC-a2 (smLC) | 75.0 | 58.5 | F | No | Adenocarcinoma |
| LC-a3* (pLC) | 67.0 | 57.2 | F | No | Adenocarcinoma |
| LC-s4 (smLC) | 68.0 | 58.5 | F | No | Squamous cell carcinoma |
| LC-s5 (smLC) | 65.0 | 62.5 | M | Yes | Squamous cell carcinoma |
| LC-a6 (smLC) | 78.0 | 55.6 | F | No | Adenocarcinoma |
| LC-a7* (pLC) | 65.0 | 60.1 | F | No | Adenocarcinoma |
| LC-a8* (pLC) | 76.0 | 56.6 | F | No | Adenocarcinoma |
| LC-a9 (smLC) | 66.0 | 64.5 | F | Yes | Adenocarcinoma |
| LC-a10 (smLC) | 64.0 | 62.5 | M | Yes | Adenocarcinoma |
| LC-a11 (smLC) | 62.0 | 62.3 | M | Yes | Adenocarcinoma |
A patient who responds to chemotherapy treatment is referred as smLC (stable metastatic lung cancer), whereas patient non-responding to the chemotherapy is referred as pLC* (progressive lung cancer).